TRCT
TOVX icon

Tower Research Capital (TRC)’s Theriva Biologics TOVX Stock Holding History

Tower Research Capital (TRC)’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,391
Closed -$2.44K – 5790
2024
Q4 		$2.44K Buy
1,391
+730
+110% +$1.07K ﹤0.01% 4840
2024
Q3 		$912 Buy
661
+655
+10,917% +$3.2K ﹤0.01% 5232
2024
Q2 		$34 Hold
6
– – ﹤0.01% 5555
2024
Q1 		$68 Hold
6
– – ﹤0.01% 5687
2023
Q4 		$62 Hold
6
– – ﹤0.01% 5754
2023
Q3 		$78 Hold
6
– – ﹤0.01% 5749
2023
Q2 		$145 Hold
6
– – ﹤0.01% 5779
2023
Q1 		$0 Hold
6
– – ﹤0.01% 6274
2022
Q4 		$0 Sell
6
-9
-60% -$163 ﹤0.01% 6379
2022
Q3 		$0 Sell
15
-29
-66% -$1.11K ﹤0.01% 6493
2022
Q2 		$2K Buy
44
+5
+13% +$286 ﹤0.01% 5605
2022
Q1 		$3K Sell
39
-198
-84% -$13.5K ﹤0.01% 5423
2021
Q4 		$16K Buy
237
+184
+347% +$17.4K ﹤0.01% 3937
2021
Q3 		$6K Buy
53
+42
+382% +$5.23K ﹤0.01% 4776
2021
Q2 		$2K Buy
+11
New +$1.58K ﹤0.01% 5078
2021
Q1 		– Sell
-59
Closed -$11.7K – 5730
2020
Q4 		$6K Buy
+59
New +$5.17K ﹤0.01% 4563
2020
Q3 		– Hold
0
– – – 5091
2020
Q2 		– Hold
0
– – – 4999
2020
Q1 		– Hold
0
– – – 3885
2019
Q4 		– Hold
0
– – – 4360
2019
Q3 		– Hold
0
– – – 4510
2019
Q2 		– Hold
0
– – – 4295
2019
Q1 		– Hold
0
– – – 4275
2018
Q4 		– Hold
0
– – – 4348
2018
Q3 		– Hold
0
– – – 4247
2018
Q1 		– Hold
0
– -$1K – 3821
2017
Q4 		– Hold
0
– – – 3369
2017
Q3 		– Sell
-3
Closed -$17.3K – 3675
2017
Q2 		$13K Sell
3
-11
-79% -$54.8K ﹤0.01% 1464
2017
Q1 		$76K Buy
14
+13
+1,300% +$90.7K 0.01% 553
2016
Q4 		$6K Buy
+1
New +$10.3K ﹤0.01% 2967
2016
Q3 		– Hold
0
– – – 4445
2016
Q2 		– Hold
0
– – – 4966
2016
Q1 		– Hold
0
– – – 3784
2015
Q4 		– Hold
0
– – – 4167
2015
Q3 		– Hold
0
– – – 2576
2015
Q2 		– Hold
0
– – – 2825
2015
Q1 		– Hold
0
– – – 3601
2014
Q4 		– Hold
0
– – – 3161
2014
Q3 		– Hold
0
– – – 3460
2014
Q2 		– Hold
0
– – – 3760
2014
Q1 		– Hold
0
– – – 3467

Other funds holding TOVX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return

Tower Research Capital (TRC)'s TOVX Position: Q1 2025 in Review

Tower Research Capital (TRC) sold out of Theriva Biologics (TOVX) in Q1 2025, closing a stake of 1,391 shares — an estimated $2.44K sold.

Tower Research Capital (TRC) first reported a position in TOVX in Q4 2016 and held it in 19 quarters. The position peaked at $76K in Q1 2017. 11 funds tracked by Wall St. Rank hold TOVX as of Q1 2025.

  • Tower Research Capital (TRC) reported no remaining Theriva Biologics position as of Q1 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,391 Theriva Biologics shares in Q1 2025, an estimated $2.44K.
  • Tower Research Capital (TRC) first reported a position in Theriva Biologics in Q4 2016 and held it in 19 quarters.
  • Tower Research Capital (TRC)'s Theriva Biologics position peaked at $76K in Q1 2017.
  • 11 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.